INMUNE BIO ($INMB) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$0.43 per share, beating estimates of -$0.48 by $0.05. The company also reported revenue of $50,000, beating estimates of $0 by $50,000.
You can see Quiver Quantitative's $INMB stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
INMUNE BIO Hedge Fund Activity
We have seen 40 institutional investors add shares of INMUNE BIO stock to their portfolio, and 20 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG added 93,092 shares (+215.7%) to their portfolio in Q4 2024, for an estimated $434,739
- MILLENNIUM MANAGEMENT LLC added 88,823 shares (+43.9%) to their portfolio in Q4 2024, for an estimated $414,803
- RENAISSANCE TECHNOLOGIES LLC added 78,600 shares (+73.3%) to their portfolio in Q4 2024, for an estimated $367,062
- CORTON CAPITAL INC. removed 76,143 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $355,587
- MORGAN STANLEY added 62,982 shares (+68.4%) to their portfolio in Q4 2024, for an estimated $294,125
- DAUNTLESS INVESTMENT GROUP, LLC removed 61,142 shares (-31.9%) from their portfolio in Q1 2025, for an estimated $477,519
- HEIGHTS CAPITAL MANAGEMENT, INC removed 60,978 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $284,767
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
